Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + oxaliplatin + cetuximab
- Development stage
- Phase 2
- Lead developer
- New Mexico Cancer Research Alliance
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This refers to a combination chemotherapy and targeted therapy regimen consisting of irinotecan, oxaliplatin, and cetuximab. Irinotecan is a small molecule topoisomerase I inhibitor that prevents DNA religation, leading to double-strand breaks and cell death. Oxaliplatin is a platinum-based antineoplastic agent that forms DNA cross-links, inhibiting DNA replication and transcription. Cetuximab is a recombinant human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in cell proliferation and survival. This specific triple combination was evaluated in a Phase II clinical trial (NCT00871169) sponsored by the New Mexico Cancer Research Alliance for the treatment of locally advanced or metastatic pancreatic cancer.
- Other names
- irinotecan hydrochloride + oxaliplatin + cetuximab
02
Targets
Beyond the preview
Go deeper on irinotecan + oxaliplatin + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + oxaliplatin + cetuximab.